Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2004

View Archived Issues

Depletion of B-cells by humanized anti-CD20 antibody in monkeys

Abatacept shows promise in the treatment of rheumatoid arthritis

Enrollment underway in study of WinRho SDF for dengue hemorrhagic fever

Cangene and DynPort seeking approval of VIG products

Orphan drug status for Efaproxyn

South African HIV trial of VGV-1 commences enrollment

Sculptra receives FDA approval for lipoatrophy

Funding at Pepgen to support advancement of Tauferon

New KSP inhibitors jointly reported by GSK and Cytokinetics

Micrologix Biotech and Strata enter agreement for MBI-226

New histamine H3 ligands and their use in obesity and other disorders

Sigma-Tau presents novel agents for diabetes, obesity, etc.

Orphan drug designation for ambrisentan for PAH

Active Pass researchers describe new antiamyloidogenic agents

Pierre Fabre and Merck & Co. sign agreement for F-50035

Novel CD80 antagonists and their use claimed by Active Biotech

Phase I study begins of IL-13-PE38QQR for newly diagnosed malignant glioma

Novel 5-HT reuptake inhibitors and 5-HT1A/5-HT2A agonists identified at Merck KGaA

NR2B-selective NMDA antagonists newly discovered at Pfizer

SBIR award supports research into proteoglycans in Alzheimer's at ProteoTech

Enrollment completed in phase II study of octreotide implant

Series B financing at Ceregene

BAY-43-9006 receives European orphan drug status for renal cell carcinoma

Emisphere selects formulation of oral heparin

AX-200 set to enter phase II for stroke

GSK provides notice to Inex to terminate topotecan agreement

Cymbalta approved for major depressive disorder

Liver-selective glucocorticoid antagonist for type 2 diabetes therapy

Antioxidant compound effective against arteriosclerosis in rodent allograft model

Novel immunotherapeutic approach to cancer therapy with dendritic cell crosslinking antibody

Exploring effective natural products for Alzheimer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...